With the price of Mounjaro set to almost triple in the UK, there are fears more and more people will turn to counterfeits.

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

S&P 500, Eli Lilly and Company, Nomura Holdings Inc ADR, The Health Care Select Sector SPDR® Fund. Read 's Market Analysis on Investing.com ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

Many Mounjaro users have considered making the swap after Eli Lilly announced prices would be increasing in the UK by 170 ...

European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...

In people with recently diagnosed type 2 diabetes and no prior cardiovascular disease, self-reported physical activity ...

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

Indianapolis: Eli Lilly and Company has announced that Anne White, executive vice president and president, Lilly Neuroscience ...